

OTC Markets

Joining us today is Jim Joyce, Chief Executive Officer of Sigyn Therapeutics Inc., which trades on our OTCQB venture market under the symbol SIGY. Sigyn is a development stage medical technology company focused on the development of blood purification devices to treat cancers and infectious disease related disorders.

Jim, thanks for joining us today.

Jim Joyce

My pleasure. Thanks for having me on.

OTC Markets

To start, can you give us a bit of background about yourself and Sigyn Therapeutics?

Jim Joyce

Sure. Well, we're based in San Diego, and we're among several publicly traded blood purification companies that are advancing therapy generally to address conditions that are beyond the reach of drugs. In our case, we're developing a blood purification therapy to enhance the benefit of cancer therapies. And our lead product, Sigyn Therapy, addresses life threatening infectious disease disorders that are not addressed with drugs at present. And this is an area where we have a lot of experience, Matt, with the exception of our CFO. All of our employees previously worked with me at a company called Athlon Medical. This was a company that I founded and built from single shareholder startup to NASDAQ company with a peak market value of slightly over 200 million dollars. And at Athlon, we worked together to develop the first therapy to receive two FDA breakthrough device designations. And then subsequently, the therapy was also the first therapy of its kind to be approved for treating a life-threatening viral infection, and this was related to the treatment of Ebola. So today the work that we're doing here at Sigyn Therapy expands upon our success at Athlon, but it's the next generation technologies that gives us broader capabilities.

OTC Markets

So you mentioned the two products, and then I'm going to ask you about both of them. But to start, I believe this is about seeking therapy, but you recently published an article about your ability to address endotoxemia. Am I pronouncing that correctly?

Jim Joyce

You nailed it, Matt.

OTC Markets

All right, sepsis and drug resistant viral and bacterial infections. Can you give our listeners an overview of your research as well as what you've done to combat the four related issues that I mentioned?

Jim Joyce

Sure. Well, all of those issues are not addressed with drug therapies. And among those, you mentioned sepsis. This is the leading cause of hospital deaths in the United States. There is a growing rate of drug-resistant bacterial infections and increasing incidence of life-threatening viral infections that are drug resistant. And endotoxemia, which you've correctly described, can be associated with these conditions. This is an issue that's a leading trigger for sepsis, and it occurs, it's the leading bacterial toxin in your gut. And when you have a viral infection, bacterial infection, there's a natural inflammatory response, and it causes permeability in your intestinal lining that allows endotoxin to seep into the bloodstream. And this can trigger a life-threatening immune response that can lead to sepsis, multiple organ failure and eventually death. So, we're addressing these conditions, and you ask, you know some of our background, we're really performing the functions of three different devices that exist. I mentioned our previous work at Athlon related to the advancement of a broad-spectrum antiviral device. We think that was a life, you know, a game-changing technology. In fact, I didn't mention it was among the top, came the top 25 invention by Time Magazine. But with Sigyn Therapy, we're addressing a broad spectrum of viral pathogens. We're also addressing bacterial toxins, including endotoxin, and then pro-inflammatory cytokines, whose dysregulated production can trigger sepsis and other life-threatening disorders. And so, previous products in the marketplace, besides the work we did at Athlon, there's a product in the marketplace to address pro-inflammatory cytokines. There's another product in the marketplace to address endotoxemia. Sigyn Therapy addresses all of those simultaneously.

OTC Markets

And so how does this tie into your drug enhancement technologies? They did mention earlier, um you know can you elaborate on the three trademarks that you have and what exactly they do and I guess how it ties into seeking therapy?

Jim Joyce

Yeah, so this is related to our pipeline, Matt. And in our pipeline, we're focused on enhancing the delivery of leading drugs to treat cancer. And this, these products include our immune prep platform to enhance the delivery of immunotherapeutic antibodies. And this includes checkpoint inhibitors as well as antibody drug conjugates. These are the top selling revenue generators for, you know, the biopharmaceutical industry and very important breakthrough drugs, but the unfortunate reality is they're very poorly delivered. Most, of vast majority of a therapeutic dose does not get delivered to its intended therapeutic targets. And so we're addressing drug decoys that are in the circulatory system to extract them prior to the administration of these drugs to improve their, improve their delivery and subsequently enhance their benefit for patients. Other products in our pipeline related to cancer include chemo prep and chemo pure. Now, chemo prep is similar to what we're doing with immune prep, but this is to enhance the delivery of chemotherapy, which people might be surprised to learn that only 2% or 3% of the drug actually gets to tumor cell targets. There's a vast array of different factors that circulate in the bloodstream that interfere with delivery and are associated directly with treatment resistant so we're advancing chemo prep to remove those particles prior to the administration of chemotherapy. And I will point out that if we could, I mean, if we could maintain the efficacy of chemotherapy with half a dose and that's an objective that in itself would cut toxicity in half. And there's ah there's a shortage of chemotherapy due to supply changes, supply chain issues around the world. And so, achieving that objective would also allow for a greater supply of the drug to be available for patients that currently may be having a hard time to get access to the drug. I mentioned earlier that a majority of chemotherapy is not delivered to cancer cell targets. This off-target chemotherapy that doesn't get to help tumor cell targets and is left to circulate in the bloodstream is more likely to cause patient toxicity as compared to patient benefit. So, in that regard, we're developing chemo pure to remove off-target chemotherapy before it can damage other healthy cells.

OTC Markets

So, all right, Jim, we talked endotoxemia. You talked the chemotherapy. We talked science. Let's talk business now. Uh, you've been trading on the OTCQB Market for over two years. Can you talk about your experience here and tell us about your goals for your current and potential investor base?

Jim Joyce

Yeah, this is a similar place where we were at in my prior company. We've been laying down the foundation for our endeavors and we've established a relationship to initiate first in human studies of seeking therapy with a you know, with some folks in the dialysis industry that have collaborated with us to establish our protocols, treatment locations, and principal investigators for first in human studies. So, you know, we've spent the last two years on the QB Venture Market, yes. But, you know, we've been very much under the radar. But we're you know preparing now to kind of do an outreach and start marketing our company to the investment community. And our goal here over the next year is to register directly to list on either the NASDAQ or the NYSE American Exchange. And we've initiated those discussions to challenging market, but I think we can achieve those objectives. This is something that we've done previously and build a company from being on the OTC that was somewhat dormant in trading to becoming a NASDAQ company that was extremely, you know, liquid and as I mentioned, achieved pretty substantial value.

OTC Markets

Jim, thank you for your time today. That brings us to the end of our podcast here. If people, investors, want to learn more about your company or want to speak to you, how can they contact you? How can they look up Sigyn Therapeutics?

Jim Joyce

Well, website is Sigyntherapeutics.com, and Sigyn is spelled S-I-G-Y-N, therapeutics.com. And you can email me directly. My email address is just the letters jj@sigyntherapeutics.com.

OTC Markets

Jim, thank you very much for your time. Sigyn Therapeutics trades under the symbol S-I-G-Y on our OTCQB Venture Market.

Jim Joyce

Thank you, Matt.

**This is an autogenerated transcript and may contain typos.*